76 results
Page 4 of 4
6-K
EX-99.1
r009cee5ed qs5hadu
23 Oct 18
MorphoSys’s Licensing Partner GSK has Reported Data on GSK3196165 from Phase 2 Study in Rheumatoid Arthritis to be Presented at the ACR Conference
6:02am
6-K
EX-99.1
rzqx9szukg7u8 qe9
22 Oct 18
Current report (foreign)
6:09am
6-K
EX-99.1
xilqy5p01gcv
9 Aug 18
MorphoSys andI-Mab Biopharma Announce China IND Submission of TJ202/MOR202
8:10am
6-K
EX-99.1
q1h pvhnclf3dns
2 Aug 18
MorphoSys AG Reports Second Quarter 2018 Financial Results
6:43am
6-K
EX-99.1
m4bqnpr
24 Jul 18
MorphoSys Announces Appointment of Jennifer Herron as President of MorphoSys US Inc. and Executive Vice President, Global Commercial
4:06pm
6-K
EX-99.2
r20qrhun4
19 Jul 18
Current report (foreign)
8:52am
6-K
EX-99.1
7y3yj 4wjbdn
19 Jul 18
Current report (foreign)
8:52am
6-K
EX-99.1
8ascr2 zfbusc
10 Jul 18
MorphoSys Announces its Licensee Janssen has Initiated a
4:06pm
6-K
EX-99.1
z9hudyk7u0q5tbp
15 Jun 18
MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018
12:00am
6-K
EX-99.1
gmk 0vr5xvm6h0mqe
15 Jun 18
MorphoSys Presents Clinical Data with Blood Cancer Candidate MOR208 in Chronic Lymphocytic Leukemia at EHA 2018 Conference
12:00am
6-K
EX-99.1
h5n81 05bd8h50o93cf5
17 May 18
Annual General Meeting of MorphoSys AG Elects New Supervisory
4:07pm
6-K
EX-99.1
jruesghg4ey 3t
17 May 18
MorphoSys Announces Presentation of Clinical Data on Proprietary
4:05pm
6-K
EX-99.1
azko8xuhgxsd6m
2 May 18
First Quarter Interim Statement
4:08pm
6-K
EX-99.1
8x2f1
2 May 18
MorphoSys AG Reports First Quarter 2018 Results
4:07pm
6-K
EX-99.1
c36n4
1 May 18
MorphoSys and Galapagos Announce Initiation of the IGUANA
4:06pm
6-K
EX-99.1
7pmknpo fbwoukrinz8
26 Apr 18
MorphoSys Announces Approval of Tremfya® (Guselkumab) in South Korea
4:06pm